Document is current
Any future updates will be listed below
-
Authors
Kaltseis, Katharina
Filippi, Vera
Frank, Florian
Eckhardt, Christine
Schiefecker, Alois
Broessner, Gregor
- License Information
-
More Information
Article History
Received: 12 September 2022
Accepted: 10 April 2023
First Online: 28 April 2023
Declarations
:
: KK, VF, CE have no potential conflict of interests to declare. FF reports personal fees from Novartis AG, personal fees from Eli Lilly and Company, and personal fees from TEVA Pharmaceutics, outside of the submitted work. AS reports personal fees from TEVA pharmaceutics, outside the submitted work. GB has received unrestricted grants, honoraria, personal fees, and travel grants from Allergan, AMGEN, Menarini, Pfizer, Linde AG, Astra Zeneca, St. Jude Medical, Reckitt Benkiser, Novartis, TEVA, Fresenius, Janssen Cilag, Lundbeck and Lilly.
: The study protocol was approved by the local ethics committee of the Medical University of Innsbruck (1056/2022) and the research was conducted in accordance with the Declaration of Helsinki. The need for informed consent was waived by the ethics committee of the Medical University of Innsbruck.
: Not applicable.
